Montelukast (Singulair) for Asthma: Benefits, FDA Black Box Warning, and Alternatives

What Is Montelukast?

Montelukast is a leukotriene receptor antagonist (LTRA), a class of oral medications that reduce airway inflammation by blocking a specific inflammatory pathway. It was first approved by the FDA in 1998 and remained a widely prescribed asthma controller for over two decades before the 2020 black box warning significantly restricted its use in mild disease.

It is available in the United States as:

• Brand name: Singulair (now primarily available as generic)
• Generics: Multiple manufacturers; equivalent efficacy
• Formulations: 10mg tablet (adults), 5mg chewable tablet (children 6-14), 4mg chewable tablet or 4mg granule packet (children 12 months to 5 years)

Montelukast is FDA-approved for:

• Asthma prophylaxis and chronic treatment in adults and children ≥12 months
• Prevention of exercise-induced bronchoconstriction in patients ≥6 years
• Relief of symptoms of seasonal and perennial allergic rhinitis in adults and children ≥6 months

How Montelukast Works

Leukotrienes are potent inflammatory chemical messengers produced primarily by eosinophils, mast cells, and basophils in response to allergen exposure and other asthma triggers. In the airways, cysteinyl leukotrienes (LTC4, LTD4, LTE4) cause:

• Bronchoconstriction (airway smooth muscle contraction)
• Mucus hypersecretion
• Airway mucosal edema (swelling)
• Increased eosinophil recruitment into the airway

Montelukast works by selectively blocking the cysteinyl leukotriene type 1 (CysLT1) receptor on airway smooth muscle and immune cells. This prevents leukotrienes from binding and triggering the inflammatory cascade. The result is reduced bronchoconstriction, less airway swelling, and decreased mucus production.

Importantly, montelukast does not block the full inflammatory cascade the way inhaled corticosteroids (ICS) do. ICS suppress broad cytokine signaling across multiple inflammatory pathways. Montelukast is pathway-specific, which means it is more effective for patients whose asthma is driven primarily by the leukotriene pathway — typically those with allergic or eosinophilic phenotypes.

FDA Black Box Warning: Neuropsychiatric Events (2020)

In March 2020, the FDA upgraded the montelukast warning to a black box warning — the strongest safety warning the FDA places on a prescription medication — for serious neuropsychiatric events. This was based on years of post-marketing surveillance reports and a growing body of clinical case evidence.

What the Warning Covers

The black box warning specifically lists the following neuropsychiatric events as reported with montelukast use:

• Agitation and aggression
• Anxiousness
• Attention and memory disturbances
• Dream abnormalities and hallucinations
• Depression
• Disorientation
• Insomnia and sleep disturbances
• Irritability and restlessness
• Obsessive-compulsive symptoms
• Suicidal thinking and behavior (suicidality), including completed suicides
• Tremor

Who Is Affected

These events have occurred in patients with and without a prior history of psychiatric illness, across all age groups — children, adolescents, and adults. The exact frequency is unknown; these are spontaneous post-marketing reports rather than controlled trial data, which means the true incidence is difficult to quantify.

FDA’s 2020 Guidance to Physicians

The FDA issued specific guidance alongside the black box warning:

• For mild asthma: Generally avoid prescribing montelukast when alternative therapies such as inhaled corticosteroids are adequate and better tolerated.
• For allergic rhinitis: Generally avoid when antihistamines or intranasal corticosteroids are adequate alternatives.
• For moderate-to-severe asthma: The risk-benefit decision is individualized; benefits may outweigh risks for patients who are failing or cannot tolerate ICS-based therapies.
• Prescribers must counsel patients and caregivers about the neuropsychiatric risks at the time of prescribing.
• Patients who experience behavior or mood changes should contact their physician promptly.

What This Means in Practice

The black box warning does not mean montelukast is universally dangerous or must be stopped immediately by all patients. It means the risk-benefit calculation has changed. For patients who are well-controlled, experiencing no neuropsychiatric side effects, and for whom alternatives are less appropriate, continuing under physician supervision may be reasonable. For patients with mild asthma who could be controlled on a low-dose inhaled corticosteroid, the FDA guidance strongly favors the inhaled option.

Who Benefits Most from Montelukast?

Clinical evidence and phenotyping data identify specific patient profiles where montelukast is most likely to provide meaningful benefit:

Who Should Generally Avoid Montelukast?

Based on FDA guidance and clinical best practice, montelukast is generally not recommended for:

• Patients with a personal or family history of depression, anxiety, suicidal ideation, or other psychiatric conditions
• Patients with mild intermittent asthma adequately controlled by a short-acting rescue inhaler (SABA alone)
• Patients with mild persistent asthma who have not first tried a low-dose inhaled corticosteroid
• Non-allergic, non-eosinophilic asthma phenotypes (montelukast’s mechanism is less relevant)
• Patients who experienced neuropsychiatric symptoms on a prior montelukast trial
• Children or adolescents with active behavioral or emotional issues, unless the clinical benefit is compelling and the patient/family are fully counseled

This is not an exhaustive list. Your physician must weigh your individual history, current medications, and asthma severity against these considerations.

Dosing and Formulations

Montelukast does not require dosage adjustment for renal impairment. Caution is advised in severe hepatic impairment. It is generally taken without regard to food, though the evening timing is preferred because airway inflammation and leukotriene levels tend to peak in the early morning hours.

How Effective Is Montelukast Compared to Other Asthma Medications?

Montelukast is a second-line controller in most international guidelines, including GINA (Global Initiative for Asthma). Head-to-head clinical trials consistently show that:

• Low-dose inhaled corticosteroids (ICS) are superior to montelukast as first-line controller therapy for mild persistent asthma, producing greater improvements in FEV1, symptom scores, and exacerbation rates
• ICS plus long-acting beta-agonist (ICS-LABA) combinations are far more effective than montelukast for moderate-to-severe asthma
• Adding montelukast to ICS provides modest additional benefit in some patients — approximately equivalent to doubling the ICS dose, but with fewer ICS-related side effects
• For exercise-induced bronchoconstriction specifically, montelukast provides consistent protection that does not diminish with daily use (unlike short-acting beta-agonists used prophylactically)

The practical takeaway: montelukast is rarely a better choice than ICS as a standalone controller. Its role is most clearly defined as an add-on for specific phenotypes or when ICS cannot be used.

Montelukast and Severe Asthma

For patients with severe uncontrolled asthma, montelukast is a distant second option compared to FDA-approved biologic therapies. Biologics such as mepolizumab (Nucala), benralizumab (Fasenra), dupilumab (Dupixent), tezepelumab (Tezspire), and omalizumab (Xolair) target specific inflammatory pathways driving severe disease with dramatically greater efficacy than montelukast. See our biologic comparison guide for details on how these agents compare by mechanism and patient eligibility.

Montelukast in Children: What Parents Need to Know

Montelukast has been prescribed to millions of children with asthma and allergic rhinitis. The black box warning applies equally to pediatric patients, and in some respects, the concerns are more acute in children because:

• Neuropsychiatric events in children may manifest differently — as behavioral changes, aggression, nightmares, or academic decline rather than classic depression or suicidal ideation
• Children may not be able to articulate mood or cognitive changes to caregivers
• The long-term consequences of neuropsychiatric events during childhood neurodevelopment are unknown

Monitoring Recommendations for Parents

If your child is prescribed montelukast, the following monitoring approach is recommended:

• Document the child’s baseline behavior, mood, and sleep patterns before starting the medication
• Observe closely during the first 4 weeks — the period when most neuropsychiatric events are reported
• Watch for: nightmares or disturbed sleep, unusual irritability or aggression, social withdrawal, speech or thought changes, mood changes inconsistent with the child’s baseline
• Contact your physician immediately if any of these changes appear — do not wait for the next scheduled appointment
• Ask your child’s school or daycare providers to report any behavioral changes they notice

If your child is currently taking montelukast without any of these side effects, do not stop abruptly without consulting your pediatric pulmonologist or allergist. Stopping asthma controller medication without a plan can trigger worsening symptoms or exacerbations.

Alternatives to Montelukast for Asthma

The right alternative depends on your asthma severity, phenotype, and comorbidities. The table below outlines the main options:

Transitioning Off Montelukast

If you and your physician decide to transition away from montelukast, the approach typically involves:

1. Initiating an appropriate alternative controller (usually an ICS or ICS-LABA) at a therapeutic dose before stopping montelukast
2. Overlapping both medications briefly to ensure the new controller is providing adequate protection
3. Tapering or stopping montelukast once the alternative is established and asthma control is confirmed
4. Scheduling a follow-up visit 4-6 weeks after the switch to assess control with spirometry and symptom review

Do not stop montelukast abruptly without a bridging plan. Sudden discontinuation can lead to worsening asthma, especially if it has been part of your regimen for a long time and your dosing of other controllers has not been adjusted upward.

Should You Stop Taking Montelukast?

This is a question your physician must answer for your specific situation. There is no universal answer. General considerations:

• Stop and seek immediate care if you or your child experiences suicidal thoughts, severe mood or behavior changes, hallucinations, or other acute psychiatric symptoms while on montelukast. Call 988 (Suicide and Crisis Lifeline) if there is immediate risk.
• Schedule a physician visit to discuss alternatives if you have mild asthma controlled by montelukast and have not been offered a trial of inhaled corticosteroids.
• Do not stop without medical guidance if montelukast is part of a multi-drug regimen for moderate-to-severe asthma or if you have AERD. Stopping could precipitate serious exacerbations.
• Continue if you are well-controlled, have no neuropsychiatric side effects, and alternatives are less suitable for your profile — as long as you and your physician review this decision regularly.

At Advanced Asthma Clinic, every patient on montelukast receives a formal medication review as part of their asthma assessment. Dr. Frank Hull evaluates whether the drug remains appropriate given the patient’s current asthma phenotype, control status, and risk profile.

Frequently Asked Questions